X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PANACEA BIOTECH ALEMBIC PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 28.4 138.1 20.6% View Chart
P/BV x 6.5 3.1 211.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
ALEMBIC PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs792149 532.4%   
Low Rs44382 538.3%   
Sales per share (Unadj.) Rs167.084.1 198.5%  
Earnings per share (Unadj.) Rs38.2-18.3 -208.5%  
Cash flow per share (Unadj.) Rs42.0-6.7 -626.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.983.7 101.4%  
Shares outstanding (eoy) m188.5261.25 307.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.4 269.3%   
Avg P/E ratio x16.2-6.3 -256.4%  
P/CF ratio (eoy) x14.7-17.2 -85.3%  
Price / Book Value ratio x7.31.4 527.0%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3837,074 1,645.1%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m4,2141,449 290.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m31,4875,154 611.0%  
Other income Rs m55100 55.2%   
Total revenues Rs m31,5425,254 600.4%   
Gross profit Rs m10,060-766 -1,312.8%  
Depreciation Rs m722711 101.6%   
Interest Rs m371,503 2.4%   
Profit before tax Rs m9,356-2,881 -324.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 26.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m2,16017 12,858.3%   
Profit after tax Rs m7,194-1,121 -641.6%  
Gross profit margin %31.9-14.9 -214.9%  
Effective tax rate %23.1-0.6 -3,958.8%   
Net profit margin %22.8-21.8 -105.0%  
BALANCE SHEET DATA
Current assets Rs m15,0663,810 395.4%   
Current liabilities Rs m7,6748,365 91.7%   
Net working cap to sales %23.5-88.4 -26.6%  
Current ratio x2.00.5 431.0%  
Inventory Days Days67156 43.0%  
Debtors Days Days4167 60.4%  
Net fixed assets Rs m8,23714,480 56.9%   
Share capital Rs m37761 615.0%   
"Free" reserves Rs m15,416903 1,707.1%   
Net worth Rs m16,0055,127 312.2%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m24,59419,433 126.6%  
Interest coverage x255.2-0.9 -27,849.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.30.3 482.8%   
Return on assets %29.42.0 1,496.9%  
Return on equity %44.9-21.9 -205.5%  
Return on capital %58.73.6 1,613.6%  
Exports to sales %55.724.5 227.3%   
Imports to sales %10.410.2 102.4%   
Exports (fob) Rs m17,5511,264 1,388.7%   
Imports (cif) Rs m3,283525 625.6%   
Fx inflow Rs m17,8111,539 1,157.1%   
Fx outflow Rs m5,318942 564.5%   
Net fx Rs m12,493597 2,091.8%   
CASH FLOW
From Operations Rs m9,304599 1,552.7%  
From Investments Rs m-3,105-438 709.0%  
From Financial Activity Rs m-1,959-303 647.4%  
Net Cashflow Rs m4,240-141 -3,000.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.6 483.3%  
FIIs % 9.1 1.3 700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.6 58.9%  
Shareholders   49,328 10,259 480.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PANACEA BIOTECH COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS